PRESS RELEASE: 52-Week Study Finds ONGLYZA(TM) -2-

26th Jun 2010 15:00

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business. For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363). ONGLYZA is a trademark of the Bristol-Myers Squibb Company. CONTACT: Media: Bristol-Myers Squibb Ken Dominski, 609-252-5251 [email protected] or AstraZeneca Corey Windett, 302-885-0034 [email protected] or Investors: Bristol-Myers Squibb John Elicker, 609-252-4611 [email protected] or AstraZeneca Karl Hard, +44-20-7304-5322 [email protected] or Clive Morris, +44-207-304-5084 [email protected] SOURCE: Bristol-Myers Squibb Company Copyright Business Wire 2010 Order free Annual Report for AstraZeneca UK Ltd Visit http://djnweurope.ar.wilink.com/?ticker=GB0009895292 or call +44 (0)208 391 6028 (END) Dow Jones Newswires June 26, 2010 10:00 ET (14:00 GMT)